Open AccessRisk of mortality and cardiovascular events following macrolide prescription in chronic rhinosinusitis patients: a cohort study using linked primary care electronic health records
Author(s) -
Elizabeth Williamson,
Spiros Denaxas,
Stephen Morris,
Caroline S. Clarke,
Mike Thomas,
Hannah Evans,
Kenan Direk,
Arturo González-Izquierdo,
Paul Little,
Valerie J. Lund,
Helen Blackshaw,
Anne G. M. Schilder,
Carl Philpott,
Claire Hopkins,
James Carpenter,
Macro programme team
Publication year - 2019
Publication title -
rhinology (amsterdam. online)/rhinology
Language(s) - English
Resource type - Journals
eISSN - 1996-8604
pISSN - 0300-0729
DOI - 10.4193/rhin18.237
Subject(s) - medicine , medical prescription , chronic rhinosinusitis , primary care , cohort , cohort study , health records , medical record , emergency medicine , pediatrics , health care , intensive care medicine , family medicine , pharmacology , economics , economic growth
Macrolide antibiotics have demonstrated important anti-inflammatory and immunomodulatory properties in chronic rhinosinusitis (CRS) patients. However, reports of increased risks of cardiovascular events have led to safety concerns. We investigated the risk of all-cause and cardiac death, and cardiovascular outcomes, associated with macrolide use.